A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
NCT ID: NCT04614948
Last Updated: 2025-02-04
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
31835 participants
INTERVENTIONAL
2020-11-12
2023-06-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants
NCT04505722
A Study of Ad26.COV2.S in Adults (COVID-19)
NCT04436276
A Study of Ad26.COV2.S in Healthy Adults (COVID-19)
NCT04894305
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
NCT04652102
A Study of Ad26.COV2.S in Adults (COVID-19)
NCT04509947
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ad26.COV2.S
Participants will receive intramuscular (IM) injection of Ad26.COV2.S vaccine on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants who have not yet received second vaccination will receive second dose of Ad26.COV2.S vaccine on Day 57, if applicable and newly enrolled participants will either receive IM injection of one dose of Ad26.COV2.S vaccine on Day 1 or two doses of Ad26.COV2.S vaccine on Day 1 and Day 57. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably within 6 to 12 months after the participant's first Ad26.COV2.S vaccination.
Ad26.COV2.S
Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.
Placebo
Participants will receive IM injection of placebo on Day 1 and Day 57 in the double-blind phase. At unblinding visit (open-label phase), participants initially receiving placebo will be offered to receive IM injection of a single dose of Ad26.COV2.S vaccine. All ongoing participants who only received a single vaccination with Ad26.COV2.S in the study will be offered to receive single booster dose of Ad26.COV2.S in the open label phase preferably within 6 to 12 months after the participant's first Ad26.COV2.S vaccination.
Ad26.COV2.S
Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.
Placebo
Placebo will be administered as IM injection on Day 1 and Day 57.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ad26.COV2.S
Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.
Placebo
Placebo will be administered as IM injection on Day 1 and Day 57.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All participants of childbearing potential must: have a negative highly sensitive urine pregnancy test at screening; and have a negative highly sensitive urine pregnancy test immediately prior to each study vaccine administration
* Participant agrees to not donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after receiving the last dose of study vaccine
* Must be willing to provide verifiable identification, has means to be contacted and to contact the investigator during the study
* Must be able to read, understand, and complete questionnaires in the electronic clinical outcome assessment (eCOA) (that is, the coronavirus disease-2019 \[COVID 19\] signs and symptoms surveillance question, the e-Diary, and the electronic patient-reported outcomes (ePROs)
Exclusion Criteria
* Participant has a known or suspected allergy or history of anaphylaxis or other serious adverse reactions to vaccines or their excipients
* Participant received or plans to receive: (a) licensed live attenuated vaccines - within 28 days before or after planned administration of study vaccine; and (b) other licensed (not live) vaccines - within 14 days before or after planned administration of study vaccine
* Participant previously received a coronavirus vaccine
* Participant received an investigational drug within 30 days (including investigational drugs for prophylaxis of COVID-19) or used an invasive investigational medical device within 30 days or received investigational immunoglobulin (Ig) or investigational monoclonal antibodies within 3 months, or received convalescent serum for COVID-19 treatment within 4 months or received an investigational vaccine (including investigational Adenoviral-vectored vaccines) within 6 months before the planned administration of the first dose of study vaccine or is currently enrolled or plans to participate in another investigational study during the course of this study
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Janssen Vaccines & Prevention B.V.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Janssen Vaccines & Prevention B.V. Clinical Trial
Role: STUDY_DIRECTOR
Janssen Vaccines & Prevention B.V.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Achieve Clinical Research, LLC
Vestavia Hills, Alabama, United States
Hope Research Institute
Phoenix, Arizona, United States
Central Phoenix Medical Clinic
Phoenix, Arizona, United States
Quality of Life Medical & Research Center, LLC
Tucson, Arizona, United States
Synexus Clinical Research US Inc
Tucson, Arizona, United States
Woodland International Research Group
Little Rock, Arkansas, United States
Synexus Clinical Research US Inc
Cerritos, California, United States
eStudySite
Chula Vista, California, United States
Ark Clinical Research
Long Beach, California, United States
Anthony Mills Medical, Inc
Los Angeles, California, United States
Benchmark Research
Sacramento, California, United States
Artemis Institute for Clinical Research
San Diego, California, United States
Paradigm Clinical Research Centers, Inc.
Wheat Ridge, Colorado, United States
JEM Research LLC
Atlantis, Florida, United States
Prestige Clinical Research Center, Inc.
Coral Gables, Florida, United States
Avail Clinical Research, LLC
DeLand, Florida, United States
Velocity Clinical Research, Hallandale Beach
Hallandale, Florida, United States
Health Awareness inc.
Jupiter, Florida, United States
Altus Research, Inc
Lake Worth, Florida, United States
Compass Research, Melbourne
Melbourne, Florida, United States
Suncoast Research Group
Miami, Florida, United States
Behavioral Clinical Research , Inc
North Miami, Florida, United States
Clinical NeuroScience Solutions Inc
Orlando, Florida, United States
Progressive Medical Research
Port Orange, Florida, United States
Meridien Research
St. Petersburg, Florida, United States
Palm Beach Research Center
West Palm Beach, Florida, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Accel Research Sites
Eatonton, Georgia, United States
The University Of Chicago Medicine
Chicago, Illinois, United States
Great Lakes Clinical Trials
Chicago, Illinois, United States
The South Bend Clinic Center for Research
South Bend, Indiana, United States
Heartland Research Associates, LLC
Newton, Kansas, United States
University of Kentucky
Lexington, Kentucky, United States
Centex Studies, Inc.
Lake Charles, Louisiana, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Centennial Medical Group
Elkridge, Maryland, United States
Optimal Research
Rockville, Maryland, United States
Meridian Clinical Research, LLC
Rockville, Maryland, United States
Henry Ford Health Systems
Detroit, Michigan, United States
Cherry Street Services, Inc.
Grand Rapids, Michigan, United States
Washington University School Of Medicine
St Louis, Missouri, United States
Hassman Research Institute, LLC.
Berlin, New Jersey, United States
Jersey Shore University Medical Center
Neptune City, New Jersey, United States
Medpharmics, LLC
Albuquerque, New Mexico, United States
Meridian Clinical Research, LLC
Endwell, New York, United States
Regional Clinical Research, Inc.
Endwell, New York, United States
Allergy Asthma Immunology of Rochester, PC (AAIR) - Research Center
Rochester, New York, United States
Richmond Behavioral Associates
Staten Island, New York, United States
American Health Network, LLC
Charlotte, North Carolina, United States
Wilmington Health Associates
Wilmington, North Carolina, United States
CTI Clinical Trial and Consulting Services
Cincinnati, Ohio, United States
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Coastal Carolina Research Center
Mt. Pleasant, South Carolina, United States
Centennial Medical Center
Nashville, Tennessee, United States
Centex Studies, Inc.
Houston, Texas, United States
Centex Studies, Inc.
Houston, Texas, United States
Texas Center for Drug Development Inc
Houston, Texas, United States
Centex Studies, Inc.
McAllen, Texas, United States
Endeavor Clinical Trials, LLC
San Antonio, Texas, United States
Tranquility Clinical Research
Webster, Texas, United States
JBR Clinical Research
Salt Lake City, Utah, United States
Alliance for Multispeciality Research
Norfolk, Virginia, United States
Anima
Alken, , Belgium
Institute of Tropical Medicine Antwerp
Antwerp, , Belgium
Center for Vaccinology (CEVAC)
Ghent, , Belgium
UZ Leuven
Leuven, , Belgium
Az Sint-Maarten
Mechelen, , Belgium
Private Practice RESPISOM Namur
Namur, , Belgium
Hospital Nossa Senhora da Conceicao S A
Porto Alegre, , Brazil
Ministerio da Saude - Hospital dos Servidores do Estado - RJ
Rio de Janeiro, , Brazil
Instituto Nacional de Infectologia Evandro Chagas (INI) - FIOCRUZ
Rio de Janeiro, , Brazil
Instituto de infectologia Emilio Ribas
São Paulo, , Brazil
Centro de Referencia E Treinamento Dst/Aids
São Paulo, , Brazil
Fundacion Cardiomet CEQUIN
Armenia, , Colombia
IPS Centro Cientifico Asisitencial Jose Luis Accini S.A.S.
Barranquilla, , Colombia
Asistencia Cientifica de Alta Complejidad S.A.S
Bogotá, , Colombia
Centro Medico Imbanaco de Cali S.A.
Cali, , Colombia
T Y C Inversiones S A S Grupsalud
Santa Marta, , Colombia
CHU de Montpellier Hopital Saint Eloi
Montpellier, , France
Hopital Cochin
Paris, , France
Hopital Saint-Antoine
Paris, , France
Groupe Hospitalier Sud Hôpital Haut-Leveque Service d'hematologie
Pessac, , France
CHU Saint Etienne Hopital Nord
Saint-Etienne, , France
Hopital Rangueil
Toulouse, , France
Hopital Purpan
Toulouse, , France
Hôpital de Brabois Adultes
Vandœuvre-lès-Nancy, , France
Klinikum rechts der Isar der TU Munchen
München, , Germany
Riverside Medical Center
Bacolod, , Philippines
West Visayas State University Medical Center
Iloilo City, , Philippines
Tropical Disease Foundation
Makati, , Philippines
Makati Medical Center
Manila, , Philippines
Medical Center Manila
Manila, , Philippines
TREAD Research Tygerberg Hospital
Cape Town, , South Africa
Centre of Tuberculosis Research Innovation
Cape Town, , South Africa
Worthwhile Clinical trials
Johannesburg, , South Africa
Peermed Clinical Trial Centre
Kempton Park, , South Africa
Dr AA Mahomed Medical Centre
Moloto South, , South Africa
VX Pharma
Pretoria, , South Africa
Dr J.M. Engelbrecht Trial Site
Somerset West, , South Africa
Be Part Yoluntu Centre
Western Cape, , South Africa
Hosp. Univ. Germans Trias I Pujol
Badalona, , Spain
Hosp. Quiron Barcelona
Barcelona, , Spain
Hosp Clinic de Barcelona
Barcelona, , Spain
Hosp Univ Vall D Hebron
Barcelona, , Spain
Hosp. Univ. de La Princesa
Madrid, , Spain
Clinica Univ. de Navarra
Madrid, , Spain
Hosp. Univ. de La Paz
Madrid, , Spain
Hosp. Quiron Madrid Pozuelo
Madrid, , Spain
Clinica Univ. de Navarra
Pamplona, , Spain
Queen Elizabeth Hospital
Birmingham, , United Kingdom
Powys Teaching Local Health Board - Bronllys Hospital
Brecon, , United Kingdom
Brighton & Sussex University Hospitals NHS Trust
Brighton, , United Kingdom
University Hospitals Bristol NHS Trust
Bristol, , United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Cambridge, , United Kingdom
Ninewells Hospital
Dundee, , United Kingdom
Royal Free Hospital
Hampstead, , United Kingdom
Leicester Royal Infirmary
Leicester, , United Kingdom
Guy's and St Thomas' Hospital
London, , United Kingdom
Imperial College London and Imperial College Healthcare NHS Trust
London, , United Kingdom
Central Manchester University Hospitals NHS Foundation Trust
Manchester, , United Kingdom
Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, , United Kingdom
University of Oxford
Oxford, , United Kingdom
Derriford Hospital
Plymouth, , United Kingdom
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, , United Kingdom
Southampton General Hospital
Southampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-Guinazu J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F; ENSEMBLE2 study group. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2022 Dec;22(12):1703-1715. doi: 10.1016/S1473-3099(22)00506-0. Epub 2022 Sep 13.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-003643-29
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
VAC31518COV3009
Identifier Type: OTHER
Identifier Source: secondary_id
CR108916
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.